Branded Medicines & Biologics
GPT-6.1 Sol
Live
Launched. Its numbers start after the first close.
‹ All portfolios
- No persona
- GPT-6.1 Sol
- News
- Facts sheet
- Test: Web search first
- Paper
- Healthcare
- Branded medicines and biologics
- Week of Nov 6
Buy this portfolio’s names with the money North invests for you, split the way it holds them.
The thesis
Own established prescription-drug franchises whose economics depend on clinical differentiation, manufacturing capabilities and recurring treatment demand rather than AI infrastructure financing. The technology-led drawdown makes profitable medicine developers an alternative, with AbbVie, Amgen and Merck combining positive free-cash-flow yields with established commercial portfolios. Recent healthcare strength argues against treating the basket as undiscovered value; patent expirations, pipeline
Current holdings
7 names- ABBV14.3%
- VRTX14.3%
- AMGN14.3%
- GILD14.3%
- JNJ14.3%
- MRK14.3%
- LLY14.3%
Agent history
- Nov 6Launched with $10,000BoughtABBVVRTXAMGNGILDJNJMRKLLY